Summary

Location
at San Diego, California and other locations
Dates
study started
estimated completion

Description

Summary

TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Official Title

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions

Keywords

Atopic Dermatitis Alopecia Hidradenitis Suppurativa Vitiligo Psoriasis IMISC Registry Observational Immune-mediated Inflammatory Skin Conditions Dermatitis, Atopic Dermatitis Eczema Hidradenitis

Eligibility

You can join if…

    1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment.
    1. Participant has plans for future visits at the site for continued management of IMISC.

You CAN'T join if...

    1. Inability to provide written informed consent/assent.
    1. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).

Locations

  • University of California - San Diego/Rady Children's Hospital accepting new patients
    San Diego California 92123 United States
  • University of California accepting new patients
    Irvine California 92697 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Target PharmaSolutions, Inc.
ID
NCT03661866
Study Type
Observational [Patient Registry]
Last Updated